Optical imaging of renal cell carcinoma with anti-carbonic anhydrase IX monoclonal antibody girentuximab

Journal of Nuclear Medicine

Volumn 55, Issue 6, 2014, Pages 1035-1040

  Muselaers, Constantijn H J ^a   Stillebroer, Alexander B ^a   Rijpkema, Mark ^a   Franssen, Gerben M ^a   Oosterwijk, Egbert ^a   Mulders, Peter F A ^a   Oyen, Wim J G ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CAIX; Girentuximab; Monoclonal antibody; Optical imaging; Renal cell carcinoma

Indexed keywords

FLUORESCENT DYE; GIRENTUXIMAB; IODINE 125; BENZENESULFONIC ACID DERIVATIVE; CARBONATE DEHYDRATASE; G250 MONOCLONAL ANTIBODY; INDOLE DERIVATIVE; IRDYE 800CW; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CANCER LOCALIZATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; FLUORESCENCE IMAGING; INTERMETHOD COMPARISON; ISOTOPE LABELING; KIDNEY CARCINOMA; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NEAR INFRARED IMAGING SYSTEM; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; CARCINOMA, RENAL CELL; CHEMISTRY; DIAGNOSTIC USE; HUMAN; IMMUNOLOGY; NUDE MOUSE; PATHOLOGY; PROCEDURES; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; BENZENESULFONATES; BIOLOGICAL TRANSPORT; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; HUMANS; INDOLES; ISOTOPE LABELING; MALE; MICE; MICE, NUDE; OPTICAL IMAGING; TISSUE DISTRIBUTION;

EID: 84903136769     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.114.137356     Document Type: Article

References (27)

1. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7:245-257.
2. Patard JJ. Incidental renal tumours. Curr Opin Urol. 2009;19:454-458.
3. Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58:398-406.
4. Weight CJ, Lythgoe C, Unnikrishnan R, Lane BR, Campbell SC, Fergany AF. Partial nephrectomy does not compromise survival in patients with pathologic upstaging to pT2/pT3 or high-grade renal tumors compared with radical nephrectomy. Urology. 2011;77:1142-1146.
5. Sutherland SE, Resnick MI, MaClennan GT, Goldman HB. Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter? J Urol. 2002;167:61-64. (Pubitemid 34024499)
6. Kovar JL, Simpson MA, Schutz-Geschwender A, Olive DM. A systematic approach to the development of fluorescent contrast agents for optical imaging of mouse cancer models. Anal Biochem. 2007;367:1-12. (Pubitemid 46938663)
7. Cohen R, Stammes MA, de Roos IH, Stigter-van Walsum M, Visser GW, van Dongen GA. Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets. EJNMMI Res. 2011;1:31.
8. Cohen R, Vugts DJ, Stigter-van Walsum M, Visser GW, van Dongen GA. Inert coupling of IRDye800CW and zirconium-89 to monoclonal antibodies for single- or dual-mode fluorescence and PET imaging. Nat Protoc. 2013;8:1010-1018.
9. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol. 2010;58:75-83.
10. Muselaers S, Mulders P, Oosterwijk E, Oyen W, Boerman O. Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma. Immunotherapy. 2013;5:489-495.
11. Ebert T, Bander NH, Finstad CL, Ramsawak RD, Old LJ. Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res. 1990;50:5531-5536. (Pubitemid 20303015)
12. 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharm. 2004;19:155-163.
13. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer. 1986;38:489-494. (Pubitemid 16006918)
14. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol. 1997;15:1529-1537. (Pubitemid 27167389)
15. Leibovich BC, Sheinin Y, Lohse CM, et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol. 2007;25:4757-4764. (Pubitemid 350086478)
16. Thiry A, Dogne JM, Masereel B, Supuran CT. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci. 2006;27:566-573. (Pubitemid 44574507)
17. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77-89. (Pubitemid 14091996)
18. van der Have F, Vastenhouw B, Ramakers RM, et al. U-SPECT-II: an ultra-high-resolution device for molecular small-animal imaging. J Nucl Med. 2009;50:599-605.
19. Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB, et al. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med. 2011;52:1778-1785.
20. van der Poel HG, Buckle T, Brouwer OR, Valdes Olmos RA, van Leeuwen FW. Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. Eur Urol. 2011;60:826-833.
21. van den Berg NS, Valdes-Olmos RA, van der Poel HG, van Leeuwen FW. Sentinel lymph node biopsy for prostate cancer: a hybrid approach. J Nucl Med. 2013;54:493-496.
22. 99mTc-nanocolloid for sentinel node identification: a validation study using lymphoscintigraphy and SPECT/CT. J Nucl Med. 2012;53:1034-1040.
23. van Dam GM, Themelis G, Crane LM, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first inhuman results. Nat Med. 2011;17:1315-1319.
24. 124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8:304-310.
25. Stillebroer AB, Boerman OC, Desar IM, et al. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol. 2013;64:478-485.
26. Divgi CR, Uzzo RG, Gatsonis C, et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol. 2013;31:187-194.
27. Muselaers CH, Boerman OC, Oosterwijk E, Langenhuijsen JF, Oyen WJ, Mulders PF. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol. 2013;63:1101-1106.